LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 129
- Registration Number
- NCT00525148
- Locations
- 🇨🇳
1200.22.88602 Veterans General Hospital, Taipei, Taiwan
🇨🇳1200.22.88601 National Taiwan University Hospital, Taipei, Taiwan
🇺🇸1200.22.28 Boehringer Ingelheim Investigational Site, Bakersfield, California, United States
Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 249
- Registration Number
- NCT00525044
- Locations
- 🇨🇳
Boehringer Ingelheim Investigational Site, Wuhan, China
🇨🇳ENT Subsidiary of Fudan University Hospital, Shanghai, China
Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 457
- Registration Number
- NCT00523991
- Locations
- 🇵🇹
205.365.1025 Boehringer Ingelheim Investigational Site, Amadora, Portugal
🇨🇿205.365.1107 Boehringer Ingelheim Investigational Site, Hradec Kralove, Czech Republic
🇨🇿205.365.1079 Boehringer Ingelheim Investigational Site, Neratovice, Czech Republic
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
- Conditions
- HIV Infections
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT00517192
- Locations
- 🇨🇦
1182.71.1002 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇧🇸1182.71.1016 Boehringer Ingelheim Investigational Site, Nassau, Bahamas
🇵🇹1182.71.3502 Boehringer Ingelheim Investigational Site, Amadora, Portugal
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
- Conditions
- Pulmonary Fibrosis
- Interventions
- Drug: placeboDrug: low dose BIBF 1120 twice dailyDrug: intermediate dose BIBF 1120 twice dailyDrug: high dose BIBF 1120 twice dailyDrug: low dose BIBF1120 once daily
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 432
- Registration Number
- NCT00514683
- Locations
- 🇦🇷
1199.30.54002 Boehringer Ingelheim Investigational Site, Mendoza, Argentina
🇧🇪1199.30.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇧🇪1199.30.32002 Boehringer Ingelheim Investigational Site, Yvoir, Belgium
BIBW 2992 (Afatinib) in Head & Neck Cancer
- Conditions
- Head and Neck NeoplasmsCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 124
- Registration Number
- NCT00514943
- Locations
- 🇺🇸
1200.28.0024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸1200.28.0001 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸1200.28.0010 Boehringer Ingelheim Investigational Site, Stanford, California, United States
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
- Conditions
- Early Parkinson Disease (Early PD)
- Interventions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 539
- Registration Number
- NCT00479401
- Locations
- 🇭🇺
248.524.36008 Boehringer Ingelheim Investigational Site, Miskolc, Hungary
🇮🇳248.524.91010 Boehringer Ingelheim Investigational Site, Hyderabad, India
🇮🇳248.524.91001 Boehringer Ingelheim Investigational Site, Karnataka, India
Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 331
- Registration Number
- NCT00472199
- Locations
- 🇬🇧
248.629.44003 Boehringer Ingelheim Investigational Site, Chorley, United Kingdom
🇪🇸248.629.3402 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇬🇧248.629.44004 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
- Conditions
- Asthma
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 296
- Registration Number
- NCT00467740
- Locations
- 🇨🇦
1222.6.004 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada
🇨🇦1222.6.006 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇺🇸1222.6.073 Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States
Pivotal Study in Advanced Parkinsons Disease Patients
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 517
- Registration Number
- NCT00466167
- Locations
- 🇦🇹
248.525.43005 Boehringer Ingelheim Investigational Site, Linz, Austria
🇰🇷248.525.82008 Boehringer Ingelheim Investigational Site, Kyeonggi-do, Korea, Republic of
🇮🇹248.525.39005 Università La Sapienza di Roma, Roma, Italy